Benjamin Jackson Sells 7,912 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) General Counsel Benjamin Jackson sold 7,912 shares of the business's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $6.38, for a total value of $50,478.56. Following the transaction, the general counsel now directly owns 120,561 shares in the company, valued at $769,179.18. This trade represents a 6.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Benjamin Jackson also recently made the following trade(s):

• On Friday, January 10th, Benjamin Jackson sold 13,272 shares of Sera Prognostics stock. The stock was sold at an average price of $7.42, for a total value of $98,478.24.
• On Monday, November 11th, Benjamin Jackson sold 4,727 shares of Sera Prognostics stock. The shares were sold at an average price of $7.32, for a total transaction of $34,601.64.

Sera Prognostics Trading Up 0.6 %

Sera Prognostics stock traded up $0.04 during midday trading on Tuesday, hitting $6.37. 134,610 shares of the stock were exchanged, compared to its average volume of 143,614. The stock has a market capitalization of $215.13 million, a price-to-earnings ratio of -6.43 and a beta of 0.86. The stock's 50-day simple moving average is $7.44 and its 200 day simple moving average is $7.31. Sera Prognostics, Inc. has a fifty-two week low of $4.98 and a fifty-two week high of $12.35.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.09 million. During the same period last year, the firm earned ($0.23) earnings per share. Equities analysts anticipate that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Trading of Sera Prognostics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SERA. Quest Partners LLC boosted its position in shares of Sera Prognostics by 533.5% during the third quarter. Quest Partners LLC now owns 6,430 shares of the company's stock worth $50,000 after buying an additional 5,415 shares during the period. SG Americas Securities LLC acquired a new position in Sera Prognostics during the 3rd quarter worth about $78,000. The Manufacturers Life Insurance Company purchased a new position in Sera Prognostics during the 2nd quarter valued at about $68,000. Prime Capital Investment Advisors LLC purchased a new position in Sera Prognostics during the 3rd quarter valued at about $104,000. Finally, Pallas Capital Advisors LLC acquired a new position in Sera Prognostics in the 4th quarter valued at about $113,000. Hedge funds and other institutional investors own 54.64% of the company's stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.